Audited Financial Results for the quarter and year ended 31st March, 2026
Outcome of Board Meeting held on 30th May, 2026
1. To consider, approve and take on records the Audited Financial Results of the Company for the quarter and year ended 31st March, 2026 pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. 2. To consider and approve the Directors’ Report with the Annexure, Corporate Governance Report, Management Discussion and Analysis Report and Notice for convening the 33rd Annual General Meeting of the Company. 3. To consider the re-appointment of Internal Auditors of the Company for the year 2026-27. 4. To take on record Disclosure of Interest of Directors. 5. Any other matter with permission of the Chair.
The meeting of the Board of Directors of the Company will be held on Saturday, 30th May, 2026 to transact the following business: 1. To consider and take on records the Audited Financial Results of the Company fo the quarter and year ended 31st March, 2026 pursunt to regulation 33 of the SEBI (LODR) Regulations, 2015. 2. To consider and approve the Directors' Report with Annexures and Notice for convening the 33rd AGM of the Company. 3. To consider the re-appointment of internal Auditors of the Company for the year 2026-27. 4. To take on record Disclosure of Interest of Directors. 5. Any other matter with the permission of the chair.
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyIshita Drugs & Industries Ltd 2CIN NO.L24231GJ1992PLC017054 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.14 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Srushti Pandya Designation: Company Secretary EmailId: ishitadrugs@gmail.com Name of the Chief Financial Officer: Sumit Agrawal Designation: Chief Financial Officer EmailId: ishitadrugs@gmail.com Date: 28/04/2026 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
Non-Applicability of Annual Secretarial Compliance Certificate for the year ended 31st March, 2026
Non - applicability of Regulation 32(1) of SEBI(LODR) Regulations, 2015 for the year ended 31st March, 2026.
Complaince Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended 31st March, 2026 as attached.
The trading window for dealing in securities of the Company by designated persons stands closed from Wednesday, 01st April, 2026 till 48 hours after the declaration of the Audited Financial Results for the quarter and Financial year ended 31st March, 2026.
Disclosure under regulation 29(2) of SEBI(SAST) Regulations, 2011 received from Ishita Pharmaceuticals, related party of Ishita Drgs and Industrie Limited.
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 3.09 | 4.40 | 3.21 | 4.50 | 3.03 | 3.27 | 4.13 | 4.56 | 5.40 | 3.07 | 3.14 | 3.06 |
| YOY Revenue Growth % | -7.97% | 55% | -1.43% | 71.18% | -1.9% | -25.5% | 28.71% | 1.5% | 78.37% | -6.3% | -24.1% | -33.05% |
| Other Income | 0.07 | 0.10 | 0.01 | 0.10 | 0.06 | 0.05 | 0.07 | 0.16 | 0.09 | 0.07 | 0.10 | 0.22 |
| Total Income | 3.16 | 4.49 | 3.22 | 4.60 | 3.09 | 3.32 | 4.20 | 4.72 | 5.49 | 3.14 | 3.23 | 3.27 |
| Total Expenses + | 2.98 | 4.22 | 3.06 | 4.23 | 2.89 | 3.07 | 3.88 | 4.34 | 5.10 | 2.91 | 3.04 | 3.00 |
| Cost of Materials Consumed | 2.24 | 3.14 | 2.36 | 3.63 | 1.85 | 2.18 | 2.92 | 3.15 | 3.80 | 1.86 | 1.92 | 2.58 |
| Employee Benefit Expense | 0.31 | 0.35 | 0.34 | 0.34 | 0.34 | 0.32 | 0.36 | 0.32 | 0.34 | 0.33 | 0.36 | 0.35 |
| Other Expenses | 0.49 | 0.54 | 0.27 | 0.35 | 0.43 | 0.48 | 0.67 | 0.39 | 0.67 | 0.66 | 0.55 | 0.33 |
| Operating Profit | 0.11 | 0.18 | 0.15 | 0.27 | 0.14 | 0.21 | 0.25 | 0.22 | 0.30 | 0.15 | 0.10 | 0.06 |
| OPM % | 3.5% | 4.1% | 4.8% | 5.9% | 4.6% | 6.3% | 6.1% | 4.9% | 5.5% | 5% | 3% | 2% |
| Profit Before Tax + | 0.18 | 0.28 | 0.16 | 0.37 | 0.20 | 0.26 | 0.32 | 0.38 | 0.39 | 0.22 | 0.19 | 0.28 |
| Tax Expense | 0.05 | 0.07 | 0.04 | 0.09 | 0.05 | 0.06 | 0.08 | 0.09 | 0.09 | 0.08 | 0.04 | 0.10 |
| Tax % | 24.7% | 23.6% | 25.5% | 23.8% | 25% | 24.6% | 25.2% | 24.7% | 21.9% | 35.3% | 19.1% | 36.4% |
| Profit After Tax | 0.14 | 0.21 | 0.12 | 0.28 | 0.15 | 0.19 | 0.24 | 0.29 | 0.30 | 0.14 | 0.16 | 0.18 |
| EPS (Basic) | 0.46 | 0.70 | 0.40 | 0.94 | 0.49 | 0.65 | 0.80 | 0.96 | 1.01 | 0.48 | 0.52 | 0.59 |
| Particulars | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
| Revenue from Operations | 14.66 | 15.00 | 15.19 | 12.07 | 14.09 | 13.95 |
| YOY Revenue Growth % | -2.25% | -1.25% | 25.81% | -14.32% | 1.01% | - |
| Other Income | 0.47 | 0.34 | 0.28 | 0.20 | 0.11 | 0.31 |
| Total Income | 15.13 | 15.33 | 15.47 | 12.27 | 14.20 | 14.26 |
| Total Expenses + | 14.05 | 14.18 | 14.48 | 11.49 | 13.15 | 13.21 |
| Cost of Materials Consumed | 10.15 | 10.11 | 11.37 | 8.21 | 9.69 | 9.56 |
| Employee Benefit Expense | 1.38 | 1.34 | 1.34 | 1.28 | 1.18 | 1.10 |
| Other Expenses | 2.20 | 1.97 | 1.65 | 1.47 | 1.65 | 1.65 |
| Operating Profit | 0.61 | 0.82 | 0.71 | 0.58 | 0.94 | 0.74 |
| OPM % | 4.1% | 5.5% | 4.7% | 4.8% | 6.6% | 5.3% |
| Profit Before Exceptional | 1.08 | 1.16 | 0.99 | 0.78 | 1.04 | 1.05 |
| Exceptional Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit Before Tax + | 1.08 | 1.16 | 0.99 | 0.78 | 1.04 | 1.05 |
| Tax Expense | 0.30 | 0.29 | 0.24 | 0.20 | 0.24 | 0.22 |
| Tax % | 27.9% | 24.9% | 24.2% | 25.9% | 22.8% | 21.3% |
| Profit After Tax | 0.78 | 0.87 | 0.75 | 0.58 | 0.80 | 0.83 |
| EPS (Basic) | 2.60 | 2.90 | 2.50 | 1.93 | 2.69 | 2.77 |
| Particulars | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
| ASSETS | ||||||
| Non-Current Assets + | 3.06 | 1.31 | 1.15 | 1.23 | 1.21 | 127,236.50 |
| Property, Plant & Equipment | 0.88 | 0.88 | 0.80 | 0.89 | 0.88 | 99,577.03 |
| Capital Work in Progress | 1.75 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Non-Current Investments | 0.35 | 0.35 | 0.27 | 0.27 | 0.27 | 22,587.47 |
| Goodwill | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Intangible Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Assets + | 9.54 | 14.98 | 9.66 | 10.18 | 10.05 | 799,256.34 |
| Inventories | 0.92 | 4.46 | 1.06 | 1.60 | 0.97 | 65,442.62 |
| Trade Receivables | 1.01 | 1.90 | 0.70 | 1.80 | 0.54 | 152,377.70 |
| Cash and Cash Equivalents | 0.15 | 0.57 | 1.83 | 0.61 | 1.99 | 175,322.07 |
| Current Investments | 4.10 | 3.52 | 3.07 | 3.12 | 3.79 | 1,000.00 |
| LIABILITIES & EQUITY | ||||||
| Total Equity | 11.57 | 10.79 | 9.92 | 9.17 | 8.60 | 779,068.10 |
| Equity Share Capital | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 | 299,030.00 |
| Other Equity | 8.58 | 7.80 | 6.93 | 6.18 | 5.61 | 480,038.10 |
| Non-Current Liabilities | 0.05 | 0.10 | 0.02 | 0.02 | 0.03 | 4,108.89 |
| Current Liabilities | 0.99 | 5.40 | 0.87 | 2.21 | 2.63 | 143,315.85 |
| Total Liabilities | 1.04 | 5.51 | 0.89 | 2.23 | 2.66 | 147,424.74 |
| Particulars | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
| Cash from Operating Activities | 3.92 | -3.64 | 2.12 | -2.90 | 3.08 | -0.67 |
| Cash from Investing Activities | -2.24 | -0.67 | 0.13 | 0.59 | -0.93 | 2.45 |
| Cash from Financing Activities | -3.81 | 4.33 | -0.87 | 1.05 | 0.00 | -0.24 |
| Net Increase/Decrease in Cash | -2.13 | 0.02 | 1.38 | -1.25 | 2.14 | 1.54 |